Advances in molecular evaluation of myeloproliferative neoplasms
Nianyi Li1, Mingyi Chen2, C Cameron Yin1
1Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abstract:
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell disorders with uncontrolled proliferation of one or more hematopoietic cell types, including myeloid, erythroid and megakaryocytic lineages, and minimal defect in maturation. Most MPN are associated with well-defined molecular abnormalities involving genes that encode protein tyrosine kinases that lead to constitutive activation of the downstream signal transduction pathways and confer cells proliferative and survival advantage. Genome-wide sequencing analyses have discovered secondary cooperating mutations that are shared by most of the MPN subtypes as well as other myeloid neoplasms and play a major role in disease progression. Without appropriate management, the natural history of most MPN consists of an initial chronic phase and a terminal blast phase. Molecular aberrations involving protein tyrosine kinases have been used for the diagnosis, classification, detection of minimal/measurable residual disease, and target therapy. We review recent advances in molecular genetic aberrations in MPN with a focus on MPN associated with gene rearrangements or mutations involving tyrosine kinase pathways.
Insights
Myeloproliferative neoplasms (MPN) involve uncontrolled blood cell growth due to molecular abnormalities. Recent advances focus on genetic aberrations in tyrosine kinase pathways for diagnosis and targeted therapy.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders characterized by uncontrolled proliferation of myeloid, erythroid, or megakaryocytic lineages.
- Most MPNs exhibit molecular abnormalities in protein tyrosine kinases, leading to constitutive pathway activation and enhanced cell survival/proliferation.
- Disease progression involves secondary cooperating mutations identified through genome-wide sequencing.
Purpose of the Study:
- To review recent advances in molecular genetic aberrations in MPNs.
- To focus on MPNs associated with gene rearrangements or mutations involving tyrosine kinase pathways.
Main Methods:
- Review of recent scientific literature on molecular genetics of MPNs.
- Focus on studies identifying gene rearrangements and mutations in tyrosine kinase pathways.
Main Results:
- MPNs are linked to specific molecular abnormalities in protein tyrosine kinases.
- Secondary mutations cooperate in disease progression across MPN subtypes.
- Molecular aberrations are crucial for MPN diagnosis, classification, residual disease detection, and targeted therapy.
Conclusions:
- Understanding molecular genetic aberrations in MPNs is critical for advancing diagnosis and treatment.
- Targeting tyrosine kinase pathways offers therapeutic opportunities for MPN patients.
